AU2017322312B2 - Peptides and uses thereof for diagnosing and treating myasthenia gravis - Google Patents

Peptides and uses thereof for diagnosing and treating myasthenia gravis Download PDF

Info

Publication number
AU2017322312B2
AU2017322312B2 AU2017322312A AU2017322312A AU2017322312B2 AU 2017322312 B2 AU2017322312 B2 AU 2017322312B2 AU 2017322312 A AU2017322312 A AU 2017322312A AU 2017322312 A AU2017322312 A AU 2017322312A AU 2017322312 B2 AU2017322312 B2 AU 2017322312B2
Authority
AU
Australia
Prior art keywords
peptide
seq
antibodies
amino acid
mir
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017322312A
Other languages
English (en)
Other versions
AU2017322312A1 (en
Inventor
Robert H. FAIRCLOUGH
Vu B. TRINH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of AU2017322312A1 publication Critical patent/AU2017322312A1/en
Application granted granted Critical
Publication of AU2017322312B2 publication Critical patent/AU2017322312B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rehabilitation Therapy (AREA)
AU2017322312A 2016-09-08 2017-09-07 Peptides and uses thereof for diagnosing and treating myasthenia gravis Ceased AU2017322312B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662384896P 2016-09-08 2016-09-08
US62/384,896 2016-09-08
PCT/US2017/050521 WO2018049053A2 (en) 2016-09-08 2017-09-07 Peptides and uses thereof for diagnosing and treating myasthenia gravis

Publications (2)

Publication Number Publication Date
AU2017322312A1 AU2017322312A1 (en) 2019-03-28
AU2017322312B2 true AU2017322312B2 (en) 2021-10-28

Family

ID=61562129

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017322312A Ceased AU2017322312B2 (en) 2016-09-08 2017-09-07 Peptides and uses thereof for diagnosing and treating myasthenia gravis

Country Status (8)

Country Link
US (1) US11422132B2 (enExample)
EP (1) EP3512873B1 (enExample)
JP (1) JP7169267B2 (enExample)
KR (1) KR102501179B1 (enExample)
CN (1) CN109996812A (enExample)
AU (1) AU2017322312B2 (enExample)
CA (1) CA3036130A1 (enExample)
WO (1) WO2018049053A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3512873B1 (en) 2016-09-08 2023-11-01 The Regents of The University of California Peptides and uses thereof for diagnosing and treating myasthenia gravis
US11986536B2 (en) 2019-03-23 2024-05-21 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
EP3715374A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the sequestration of undesirable antibodies in a patient
WO2020231999A1 (en) * 2019-05-13 2020-11-19 The Trustees Of The University Of Pennsylvania Compositions and methods of acetylcholine receptor chimeric autoantibody receptor cells
WO2021236724A2 (en) * 2020-05-20 2021-11-25 Remd Biotherapeutics, Inc. Human endothelin receptor a (etar) antagonist antibodies
CN112029880B (zh) * 2020-09-15 2023-04-28 石家庄市人民医院(石家庄市第一医院、石家庄市肿瘤医院、河北省重症肌无力医院、石家庄市心血管病医院) 用于重症肌无力的检测的微生物及应用
KR20230074552A (ko) 2020-09-24 2023-05-30 아블레비아 바이오테크 게엠베하 중증 근무력증의 예방 또는 치료용 화합물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3391831B2 (ja) * 1993-01-13 2003-03-31 株式会社クラレ 環状ペプチド
US20020081652A1 (en) * 1997-05-07 2002-06-27 Sara Fuchs Recombinant fragments of the human acetylcholine receptor and their use for treatment of myasthenia gravis
JP2003509045A (ja) 1999-09-15 2003-03-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ニコチン性アセチルコリン受容体：アルファ１０サブユニット
US20050048066A1 (en) * 2000-03-31 2005-03-03 Shrikant Deshpande Identification of potential immunodominant acetylcholine receptor alpha subunit
JP4283812B2 (ja) 2006-01-06 2009-06-24 財団法人工業技術研究院 重症筋無力症の診断方法およびそのキット
WO2010014723A1 (en) * 2008-07-29 2010-02-04 The Board Of Regents Of The University Of Texas System Methods and composition related to acetylcholine receptor conjugates
JP4495776B1 (ja) 2009-07-30 2010-07-07 日本製薬株式会社 融合蛋白質
EP3512873B1 (en) 2016-09-08 2023-11-01 The Regents of The University of California Peptides and uses thereof for diagnosing and treating myasthenia gravis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Vu Bao Trinh, "Therapeutic peptide mimics of the acetylcholine receptor main immunogenic region for treating myasthenia gravis", Ph.D. Thesis. University of California, ProQuest Dissertations Publishing, (2013-01-01), ISBN 978-1-303-44402-9 *

Also Published As

Publication number Publication date
EP3512873B1 (en) 2023-11-01
CA3036130A1 (en) 2018-03-15
JP2019531716A (ja) 2019-11-07
EP3512873C0 (en) 2023-11-01
AU2017322312A1 (en) 2019-03-28
WO2018049053A3 (en) 2018-05-17
WO2018049053A2 (en) 2018-03-15
EP3512873A4 (en) 2020-03-18
US20200033338A1 (en) 2020-01-30
JP7169267B2 (ja) 2022-11-10
KR102501179B1 (ko) 2023-02-16
KR20190045323A (ko) 2019-05-02
CN109996812A (zh) 2019-07-09
EP3512873A2 (en) 2019-07-24
US11422132B2 (en) 2022-08-23

Similar Documents

Publication Publication Date Title
AU2017322312B2 (en) Peptides and uses thereof for diagnosing and treating myasthenia gravis
Warren et al. Fine specificity of the antibody response to myelin basic protein in the central nervous system in multiple sclerosis: the minimal B-cell epitope and a model of its features.
JP6494565B2 (ja) オリゴマー特異アミロイドベータエピトープおよび抗体
US20110268758A1 (en) Tuberculosis antigen detection assays and vaccines
US20210347824A1 (en) Antigenic peptides and uses thereof for diagnosing and treating autism
JP2000507232A (ja) 慢性関節リウマチの病理発生に必要な関節炎誘発性ペプチドに対して免疫防御を誘発するために有用なワクチン組成物と方法
JPH09502346A (ja) 自己免疫疾患に関連するプロトコールにおけるミエリン希突起神経膠細胞糖蛋白質およびそのペプチド部分の使用
AU2012264943A1 (en) Means and methods for diagnosing and treating multiple sclerosis
JPH02479A (ja) ｓｎＲＮＰ−Ａ抗原及びそのフラグメント
US20220324913A1 (en) Antigenic neuron specific enolase peptides for diagnosing and treating autism
US7276483B1 (en) Small peptides for the treatment of Alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders
US20030215884A1 (en) Method of regenerating neurons
Popiolek Characterization of the D-amino acid oxidase interactome
US20160030544A1 (en) Immunogenic composition to neisseria
WO2003000718A2 (en) Polypeptides comprising t cell epitopes from alpha-fodrin and the uses thereof in treatment of sjögren's syndrome

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired